Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/15 cls
Anesiva (ANSV) Rodman Elemer Piros New Market outperform 1% $6.60
Piros set a $9 target. He expects FDA to approve ANSV's NDA for Zingo to treat acute pain associated with venous access procedures in children in 4Q07 and believes the company will launch the product for children in 2008 and for adults in 2009. He estimates Zingo will achieve peak annual sales of about $150M in 2013.
Array (ARRY) Oppenheimer Cory Kasimov New Buy -4%

Read the full 887 word article

How to gain access

Continue reading with a
two-week free trial.